Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai, shares the first overall survival (OS) data update on the CheckMate 274 trial, which he gave at the 2024 European Association of Urology Congress. In this study, adjuvant nivolumab demonstrated OS benefit for patients with high-risk muscle invasive bladder cancer (MIBC), especially in those with PD-L1-positive disease. ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Researchers analyzed the effects of NAC on complete and overall response as well as cancer-specific survival after RT.
Patients received 68Ga-FAP-2286 PET, and investigators recorded the SUVmax of 68Ga-FAP-2286 PET-positive lesions.
Data from 458 patients who underwent RC between October 2005 and October 2020 and 146 in the PURE-01 trial was analyzed.
Dr. Geynisman highlights the CheckMate 274 study into long-term survival following treatment with adjuvant nivolumab.
Tanya Jindal discusses the safety and efficacy of neoadjuvant atezolizumab prior to radical cystectomy for MIBC.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Advertisement
Advertisement
Latest News
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
